



NextPharma Technologies Granted License to Manufacture Veterinary Products

Surrey, UK, 7th January 2008: NextPharma Technologies, a leading provider of pharmaceutical product development, contract manufacturing, temperature controlled storage and distribution outsourcing services, is pleased to announce that its site at Waltrop, Germany has been granted a license to manufacture and package veterinary products. The site is currently negotiating a manufacturing agreement with its first veterinary product customer.

Of NextPharma's seven manufacturing plants, five (Waltrop, Bielefeld, Göttingen and Berlin in Germany, and Limay in France) have licenses to manufacture veterinary products.

Dr. Hermann Osterwald - Managing Director - Contract Manufacturing Services for NextPharma commented: "We are pleased that another of our plants has been granted a license to manufacture and package veterinary products. It represents a further extension of our capabilities to the pharmaceutical and biotechnology industry."

NextPharma develops, manufactures, packages, and distributes a broad range of products and formulations for its customers from tablets and capsules to antibiotics, hormones and controlled release medicines. It has an established leadership position in the high technology area of injectables manufacturing, with particular expertise in product development and manufacture of oncology medicines.

-Ends-

CONTACT:**NextPharma Technologies:**

Dr Hermann Osterwald, Managing Director Contract Manufacturing Services

Tel + 49 551 382 105

Notes to Editors:**About NextPharma**

NextPharma Technologies, headquartered in the UK and founded in 2000, is a world class provider of product development, contract manufacturing and distribution outsourcing services to the pharmaceutical, specialty pharmaceutical, generics and biotech industry.

It offers a broad range of services from early phase product development, through clinical trials supplies to high volume commercial manufacturing. NextPharma is a world leader in lyophilization, sterile fill-finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled substances. Its sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules.

NextPharma operates globally with seven product development centres, seven manufacturing plants and six storage and distribution sites across Europe and North America employing over 1,200 people. Across these locations NextPharma has built-up a strong track record in the development and manufacture of cytotoxics, hormones, antibiotics, pellets, sterile, solid, semi-solid, liquid and dry dosage forms, supplying customers in North America, Europe and Japan.

NextPharma has a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.